Format

Send to

Choose Destination
Anticancer Res. 2016 Jul;36(7):3651-7.

Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy.

Author information

1
Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
2
Kanonji Institute, Research Foundation for Microbial Diseases of Osaka University, Kagawa, Japan.
3
Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
4
Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan Central Research Institute for Advanced Molecular Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan smiya@cis.fukuoka-u.ac.jp.

Abstract

BACKGROUND/AIM:

Heparin-binding epidermal growth factor-like growth factor (HB-EGF), which belongs to the epidermal growth factor family, is a rational therapeutic target for triple-negative breast cancer (TNBC). This study aimed to assess the anti-tumor efficacy of intravenous (i.v.) HB-EGF-specific inhibitor (CRM197) for TNBC.

MATERIALS AND METHODS:

NOD/SCID mice were subcutaneously injected withTNBC cells, MDA-MB-231, and, then, treated with i.v. CRM197 in either dose- or frequency-dependent manners, using an advanced cancer model and an adjuvant therapy model. Tumor volume and mouse body weight were calculated weekly. Statistical significance was assessed by the Mann-Whitney U-test.

RESULTS:

Mice that received i.v. CRM197 showed a significant anti-tumor effect in dose- and frequency-dependent manners in both models. However, their body weight did not differ significantly among groups.

CONCLUSION:

These results suggest that i.v. CRM197 is an effective treatment for TNBC.

KEYWORDS:

CRM197; HB-EGF; triple-negative breast cancer

PMID:
27354636
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center